Limits...
Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis.

Kim SH, Koh IS, Minn YK - J Clin Neurol (2015)

Bottom Line: In addition, two out of the three tumors were found to be at an early clinical stage.All of the cases survived without recurrence over follow-up periods of at least 5 years.The association of this condition with MG is not as rare as was previously thought.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT

Background and purpose: The World Health Organization (WHO) has classified thymic carcinoma and other thymomas (types A, AB, and B) as different neoplasms. Myasthenia gravis (MG) is an early sign of thymoma and theoretically does not accompany thymic carcinoma; however, cases of thymic carcinoma with MG have been reported. Whether thymic carcinoma can accompany MG has yet to be established.

Methods: The medical records of patients who underwent thymectomy for MG between 1990 and 2011 in a single hospital were reviewed. All cases with the diagnostic code of "thymic carcinoma" or "thymoma type C" (old terminology) were selected. A pathologist re-reviewed the pathologic specimens using the new WHO criteria. The rate of thymic carcinoma among these MG patients was then calculated.

Results: A total of 81 patients with MG had thymic tumors, 10 of whom had thymic carcinomas or thymoma type C. Seven cases of well-differentiated thymic carcinomas (type B3) were excluded, leaving three (3.7%) cases of thymic carcinoma with MG. All three of these cases were type B3 thymoma with a focal squamous cell carcinoma component that was very small and well demarcated. In addition, two out of the three tumors were found to be at an early clinical stage. All of the cases survived without recurrence over follow-up periods of at least 5 years.

Conclusions: Thymic carcinoma transformation from thymoma can occur during the early stages of thymoma. The association of this condition with MG is not as rare as was previously thought. Thymic carcinomas accompanying MG had a predominant B3 thymoma component with a focal thymic carcinoma area (squamous cell carcinoma).

No MeSH data available.


Related in: MedlinePlus

Pathologic findings of case 2. Focal thymic carcinoma with an abundant thymoma (thymoma type B3) component. Low-power view showing a multinodular mass with extension to the peritumoral fat tissue [circle; hematoxylin-eosin stain (H-E); magnification, ×12] (A). The tumor is composed of abundant type B3 tissue (B: H-E; magnification, ×40; C: H-E, magnification, ×400) (B, C) and a focal thymic carcinoma component (squamous cell carcinoma) in the circled area (H-E; magnification, ×400) (D). Strong immunoreactivity for p63, a squamous cell differentiation marker, is found in the thymic carcinoma area (p63 immunostaining; magnification, ×400) (E). There is no p63 reactivity in the conventional thymoma B3 area (p63 immunostaining; magnification, ×400) (F).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4596109&req=5

Figure 1: Pathologic findings of case 2. Focal thymic carcinoma with an abundant thymoma (thymoma type B3) component. Low-power view showing a multinodular mass with extension to the peritumoral fat tissue [circle; hematoxylin-eosin stain (H-E); magnification, ×12] (A). The tumor is composed of abundant type B3 tissue (B: H-E; magnification, ×40; C: H-E, magnification, ×400) (B, C) and a focal thymic carcinoma component (squamous cell carcinoma) in the circled area (H-E; magnification, ×400) (D). Strong immunoreactivity for p63, a squamous cell differentiation marker, is found in the thymic carcinoma area (p63 immunostaining; magnification, ×400) (E). There is no p63 reactivity in the conventional thymoma B3 area (p63 immunostaining; magnification, ×400) (F).

Mentions: All three cases of thymic carcinoma had a predominant B3 or B2 thymoma area with a focal, well-demarcated squamous cell carcinoma area and overt cytologic atypia; two patients had a type B3 thymoma and the other patient had a type B2+B3 thymoma (a thymic carcinoma portion was seen in the B3 area). Thymic carcinoma portions were clearly identifiable from thymoma portions, and their areas were much smaller than that of the thymoma (Fig. 1A-D). The thymic carcinoma area exhibited strong immunoreactivity for p63, which is a squamous cell differentiation marker; the conventional thymoma B3 tissue was not p63 immunoreactive (Fig. 1E and F).


Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis.

Kim SH, Koh IS, Minn YK - J Clin Neurol (2015)

Pathologic findings of case 2. Focal thymic carcinoma with an abundant thymoma (thymoma type B3) component. Low-power view showing a multinodular mass with extension to the peritumoral fat tissue [circle; hematoxylin-eosin stain (H-E); magnification, ×12] (A). The tumor is composed of abundant type B3 tissue (B: H-E; magnification, ×40; C: H-E, magnification, ×400) (B, C) and a focal thymic carcinoma component (squamous cell carcinoma) in the circled area (H-E; magnification, ×400) (D). Strong immunoreactivity for p63, a squamous cell differentiation marker, is found in the thymic carcinoma area (p63 immunostaining; magnification, ×400) (E). There is no p63 reactivity in the conventional thymoma B3 area (p63 immunostaining; magnification, ×400) (F).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4596109&req=5

Figure 1: Pathologic findings of case 2. Focal thymic carcinoma with an abundant thymoma (thymoma type B3) component. Low-power view showing a multinodular mass with extension to the peritumoral fat tissue [circle; hematoxylin-eosin stain (H-E); magnification, ×12] (A). The tumor is composed of abundant type B3 tissue (B: H-E; magnification, ×40; C: H-E, magnification, ×400) (B, C) and a focal thymic carcinoma component (squamous cell carcinoma) in the circled area (H-E; magnification, ×400) (D). Strong immunoreactivity for p63, a squamous cell differentiation marker, is found in the thymic carcinoma area (p63 immunostaining; magnification, ×400) (E). There is no p63 reactivity in the conventional thymoma B3 area (p63 immunostaining; magnification, ×400) (F).
Mentions: All three cases of thymic carcinoma had a predominant B3 or B2 thymoma area with a focal, well-demarcated squamous cell carcinoma area and overt cytologic atypia; two patients had a type B3 thymoma and the other patient had a type B2+B3 thymoma (a thymic carcinoma portion was seen in the B3 area). Thymic carcinoma portions were clearly identifiable from thymoma portions, and their areas were much smaller than that of the thymoma (Fig. 1A-D). The thymic carcinoma area exhibited strong immunoreactivity for p63, which is a squamous cell differentiation marker; the conventional thymoma B3 tissue was not p63 immunoreactive (Fig. 1E and F).

Bottom Line: In addition, two out of the three tumors were found to be at an early clinical stage.All of the cases survived without recurrence over follow-up periods of at least 5 years.The association of this condition with MG is not as rare as was previously thought.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT

Background and purpose: The World Health Organization (WHO) has classified thymic carcinoma and other thymomas (types A, AB, and B) as different neoplasms. Myasthenia gravis (MG) is an early sign of thymoma and theoretically does not accompany thymic carcinoma; however, cases of thymic carcinoma with MG have been reported. Whether thymic carcinoma can accompany MG has yet to be established.

Methods: The medical records of patients who underwent thymectomy for MG between 1990 and 2011 in a single hospital were reviewed. All cases with the diagnostic code of "thymic carcinoma" or "thymoma type C" (old terminology) were selected. A pathologist re-reviewed the pathologic specimens using the new WHO criteria. The rate of thymic carcinoma among these MG patients was then calculated.

Results: A total of 81 patients with MG had thymic tumors, 10 of whom had thymic carcinomas or thymoma type C. Seven cases of well-differentiated thymic carcinomas (type B3) were excluded, leaving three (3.7%) cases of thymic carcinoma with MG. All three of these cases were type B3 thymoma with a focal squamous cell carcinoma component that was very small and well demarcated. In addition, two out of the three tumors were found to be at an early clinical stage. All of the cases survived without recurrence over follow-up periods of at least 5 years.

Conclusions: Thymic carcinoma transformation from thymoma can occur during the early stages of thymoma. The association of this condition with MG is not as rare as was previously thought. Thymic carcinomas accompanying MG had a predominant B3 thymoma component with a focal thymic carcinoma area (squamous cell carcinoma).

No MeSH data available.


Related in: MedlinePlus